ABBOTT PARK, Ill., Jan. 18, 2017
/PRNewswire/ -- Abbott (NYSE: ABT) today announced the
European launch of the new Proclaim™ DRG Neurostimulation System,
designed to deliver dorsal root ganglion (DRG) stimulation to
patients suffering from chronic neuropathic pain. Through the
Proclaim platform's Bluetooth® wireless technology and
iOS™ software, the Proclaim DRG Neurostimulation System offers
patients a more intuitive therapy experience, compared to current
systems with traditional controllers that can be difficult to
operate. This new system will improve the experience of how
patients interact with their device, which may lead more patients
to consider DRG stimulation for the treatment of chronic
neuropathic pain.
Neuropathic pain represents one of the most prevalent yet
under-treated forms of chronic pain in the world and impacts nearly
10 percent of the European population. Stimulation with Abbott's
Proclaim DRG Neurostimulation System targets nerves within the DRG,
a spinal structure packed with sensory nerves. As a result, DRG
stimulation has been clinically proven to provide superior pain
relief over traditional spinal cord stimulation (SCS) therapy by
directly targeting the area of the body where pain occurs to
improve quality of life.
Abbott is the first and only company to offer a neurostimulation
device designed for DRG therapy and targeted relief of certain
types of chronic pain. The approval of the Proclaim DRG
Neurostimulation System provides patients with chronic neuropathic
pain access to the company's Proclaim platform, a magnetic
resonance (MR)-conditional recharge-free system offering
best-in-class programming, upgradeability and increased battery
capacity. The Proclaim DRG Neurostimulation System also utilizes an
iPod touch™ mobile digital device patient controller that offers
wireless communication via Bluetooth wireless technology.
"Many patients battling chronic neuropathic pain have not found
adequate relief from other forms of treatment, which is why dorsal
root ganglion stimulation has been such an important therapeutic
advancement for pain specialists worldwide," said Harold Nijhuis, M.D., an anesthesiologist from
St. Antonius Ziekenhuis, Niuwegein, the
Netherlands. "With the approval of the Proclaim DRG System,
I am able to address chronic focal pain for my patients while
offering them access to new, patient-centric benefits and features
to improve their therapy experience."
The Proclaim DRG Neurostimulation System supports Abbott's focus
on helping physicians manage patients with difficult-to-treat
chronic pain in specific areas of the upper and lower body, such as
the foot, knee, hip or groin. Clinical research, such as the
ACCURATE study, has demonstrated that DRG therapy can provide
superior pain relief in patients with complex regional pain
syndrome (CRPS) and other focal chronic neuropathic pain conditions
compared to traditional spinal cord stimulation therapy.
"Abbott continues to pursue innovative solutions for chronic
pain because far too many patients with chronic intractable pain
battle symptoms that are not adequately managed with current
therapies," said Allen Burton, M.D.,
medical director of neuromodulation at Abbott. "Our Proclaim DRG
Neurostimulation System addresses this unmet need by offering a
therapy that is superior to traditional spinal cord stimulation
combined with patient-friendly technology."
Note: Apple and iPod touch are trademarks of Apple,
Inc. Bluetooth is a trademark of Bluetooth SIG,
Inc.
About Abbott's Chronic Pain Portfolio:
Chronic pain
affects approximately 1.5 billion people worldwide, more than heart
disease, cancer and diabetes combined. The condition can negatively
impact personal relationships, work productivity and a patient's
daily routine. Abbott is a global leader in the development of
chronic pain therapy solutions and the only medical device
manufacturer in the world to offer radiofrequency ablation (RFA)
and spinal cord stimulation (SCS) therapy solutions including
BurstDR stimulation and stimulation of the dorsal root ganglion
(DRG) for the treatment of chronic pain.
About Abbott:
At Abbott, we're committed to helping
people live their best possible life through the power of health.
For more than 125 years, we've brought new products and
technologies to the world -- in nutrition, diagnostics, medical
devices and branded generic pharmaceuticals -- that create more
possibilities for more people at all stages of life. Today, 74,000
of us are working to help people live not just longer, but better,
in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-announces-european-launch-of-the-proclaim-drg-neurostimulation-system-for-the-management-of-chronic-neuropathic-pain-300392552.html
SOURCE Abbott